Aberdeen Group
PYXS icon

Aberdeen Group’s Pyxis Oncology PYXS Stock Holding History

Aberdeen Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-913,045
Closed -$1M – 976
2025
Q2 		$1M Hold
913,045
– – ﹤0.01% 829
2025
Q1 		$895K Hold
913,045
– – ﹤0.01% 826
2024
Q4 		$1.42M Hold
913,045
– – ﹤0.01% 791
2024
Q3 		$3.35M Buy
913,045
+204,742
+29% +$716K 0.01% 714
2024
Q2 		$2.34M Hold
708,303
– – ﹤0.01% 734
2024
Q1 		$3.02M Hold
708,303
– – 0.01% 737
2023
Q4 		$1.27M Buy
+708,303
New +$1.21M ﹤0.01% 818

Other funds holding PYXS

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Aberdeen Group's PYXS Position: Q3 2025 in Review

Aberdeen Group sold out of Pyxis Oncology (PYXS) in Q3 2025, closing a stake of 913,045 shares — an estimated $1M sold.

Aberdeen Group first reported a position in PYXS in Q4 2023 and held it in 7 quarters. The position peaked at $3.35M in Q3 2024. 73 funds tracked by Wall St. Rank hold PYXS as of Q3 2025.

  • Aberdeen Group reported no remaining Pyxis Oncology position as of Q3 2025 after selling out during the quarter.
  • Aberdeen Group sold 913,045 Pyxis Oncology shares in Q3 2025, an estimated $1M.
  • Aberdeen Group first reported a position in Pyxis Oncology in Q4 2023 and held it in 7 quarters.
  • Aberdeen Group's Pyxis Oncology position peaked at $3.35M in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2025.

Based on Aberdeen Group's 13F filing for Q3 2025, filed 7 Nov 2025.